ESC 365 - The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

ESC Premium Access

The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells

Session: PCSK9 inhibitors: from cells to patients

Topic: Lipid-Lowering Agents

Speaker: Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Osnat Itzhaki Ben Zadok

Rabin Medical Center, Petah Tikva (Israel)

0 follower

4 more presentations in this session

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

Speaker: Professor S. Nicholls (Melbourne, AU)

The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.

Speaker: Mrs A. Tsouka (Ioannina, GR)

Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use

Speaker: Doctor S. Mulverstedt (Copenhagen, DK)

Positioning PCSK9 inhibitors therapy in clinical practice.

Speaker: Professor K. Ray (London, GB)

Access the full session

PCSK9 inhibitors: from cells to patients

Speakers: Doctor O. Itzhaki Ben Zadok, Professor S. Nicholls, Mrs A. Tsouka, Doctor S. Mulverstedt, Professor K. Ray

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources